Inhibitors of RNA dependent RNA polymerase and uses thereof

• US 20040106785A1
• Filed: 07/25/2003
• Published: 06/03/2004
• Est. Priority Date: 07/25/2002
• Status: Abandoned Application

• Current Assignee: Micrologix Biotech Incorporated
• Original Assignee: Micrologix Biotech Incorporated
• Inventors: Fournier, Eric, Deziel, Robert, Roland, Arlene
• Application Number:
  US10/628,086
• Publication Number:
  US 20040106785A1
• Time in Patent Office: Days
• US Class Current: 536/28.4
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Abstract

The invention herein provides novel viral DNA polymerase compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with viral DNA polymerase activity, and processes and intermediates useful for preparing such compounds.

Claims

1. A compound and pharmaceutically acceptable salts thereof according to structural formula (I):

2. The compound of claim 1 and pharmaceutically acceptable salts thereof according to structural formula (II):

3. The compound of claim 1 and pharmaceutically acceptable salts thereof according to structural formula (III):

4. A pharmaceutical composition comprising a compound according to any one of claims 1-3, and a pharmaceutically acceptable carrier, diluent, or excipient.

5. A method of treating or preventing a disease or condition associated with DNA or RNA processing enzymes, comprising administering to a subject in need thereof a pharmaceutical composition of claim 4 in an amount effective to treat or prevent said disease or condition associated with DNA or RNA processing enzymes.

6. The method of claim 5 wherein the disease or condition is a viral disease.

7. The method of claim 6 wherein the viral disease is caused by hepatitis C virus (HCV) or human immunodeficiency virus (HIV).

8. The method of claim 5 wherein said composition further comprises a second therapeutic agent.

9. The method of claim 5 wherein said composition further comprises a second therapeutic agent selected from the group consisting of an inhibitor of nucleoside reverse transcriptase, a non-nucleoside reverse transcriptase inhibitor, a helicase inhibitor, an RNase H inhibitor, a kinase inhibitor, and a protease inhibitor.

10. A method of modulating the activity of a DNA or RNA processing enzymes, the method comprising contacting a DNA or RNA processing enzyme with a modulatory amount of a compound or composition as described in any one of claims 1-4.

11. The method of claim 10 wherein the DNA or RNA processing enzyme being modulated is RNA-dependent RNA polymerase.

12. The method of claim 11 wherein the RNA-dependent RNA polymerase is non-structural protein 5B from HCV.